A serum-free cryopreservation solution contains a biomimetic ice control material, a polyol, a water-soluble sugar, and a buffer solution margin. The bionic ice control material can be polyvinyl alcohol or an amino acid compound. The cryopreservation liquid of the present invention uses the bionic ice control material as the main component, does not contain serum, has low toxicity, and can achieve a cell survival rate that is the same as, or higher than, existing cryopreservation solutions.

Provided is a method for obtaining the germ cell lineage of an oviparous vertebrate more efficiently than conventional techniques. A host oviparous vertebrate is prepared at a developmental stage after the development of black pigmentary cells in the retina and before the formation of multiple layers of germ cells in the genitals, and isolated undifferentiated germ cells from a donor oviparous vertebrate are transplanted into the host oviparous vertebrate.

The present disclosure relates to methods for increasing telomere length in one or more human cells and/or increasing genome stability of one or more human cells, for example by contacting one or more human cells with an agent that increases expression of Zscan4 in the one or more human cells. Methods of treating a subject in need of telomere lengthening, treating a disease or condition associated with a genomic and/or chromosome abnormality, of rejuvenating one or more human cells, of rejuvenating tissues or organs, and of rejuvenating a subject in need thereof, for example by contacting one or more human cells in the subject with an agent that increases expression of Zscan4, or by administering to a subject in need thereof, an agent that increases expression of Zscan4 are also provided.

The present disclosure relates to methods for increasing telomere length in one or more human cells and/or increasing genome stability of one or more human cells, for example by contacting one or more human cells with an agent that increases expression of Zscan4 in the one or more human cells. Methods of treating a subject in need of telomere lengthening, treating a disease or condition associated with a genomic and/or chromosome abnormality, of rejuvenating one or more human cells, of rejuvenating tissues or organs, and of rejuvenating a subject in need thereof, for example by contacting one or more human cells in the subject with an agent that increases expression of Zscan4, or by administering to a subject in need thereof, an agent that increases expression of Zscan4 are also provided.

Featured are methods, compositions, and apparatuses for the in vitro maturation of oocytes. In particular, the disclosure features methods of inducing oocyte maturation in vitro, by co-culturing a female subject's oocytes with an ex vivo composition containing a plurality of ovarian support cells (e.g., granulosa cells). Additional methods for administering follicular triggering agents and retrieving oocytes from the female subject are provided. Such methods, compositions, and apparatuses are particularly useful for assisted reproduction technology (ART) procedures.

The present invention relates to methods of rejuvenating aged oocytes using young somatic cells through the generation of chimeric follicles. The chimeric follicles defined herein may be used to treat infertility or improve fertility in female subjects.

The present invention relates to a nucleic acid molecule encoding (I) a polypeptide having the activity of an endonuclease, which is (a) a nucleic acid molecule encoding a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1; (b) a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO: 2; (c) a nucleic acid molecule encoding an endonuclease, the amino acid sequence of which is at least 70% identical to the amino acid sequence of SEQ ID NO: 1; (d) a nucleic acid molecule comprising or consisting of a nucleotide sequence which is at least 50% identical to the nucleotide sequence of SEQ ID NO: 2; (e) a nucleic acid molecule which is degenerate with respect to the nucleic acid molecule of (d); or (f) a nucleic acid molecule corresponding to the nucleic acid molecule of any one of (a) to (e) wherein T is replaced by U; (II) a fragment of the polypeptide of (I) having the activity of an endonuclease. Also, the present invention relates to a vector comprising the nucleic acid molecule and a protein encoded by said nucleic acid molecule. Further, the invention relates to a method of modifying the genome of a eukaryotic cell and a method of producing a non-human vertebrate or mammal.

The present invention relates to methods and compositions for increasing Ovum Pick-Up in Bos taurus cows using Follicle Stimulating Hormone.

The present disclosure discloses a composition, method and application thereof for improving the quality of in vitro maturation of oocytes and the pregnancy rate after in vitro produced embryos transfer. The present disclosure aims at the problems of low maturation rate and poor subsequent embryo development potential caused by metabolic disorders during in vitro maturation of oocytes, and provides a composition including two or more regulators in vitamin C, L-carnitine and thrombopoietin to regulate the metabolism of oocytes, thereby greatly improving the in vitro maturation rate of oocytes and the subsequent embryo development potential. The present disclosure not only improves the efficiency of in vitro embryo production of livestock, but also provides a reference for improving the efficiency of human assisted reproductive technology. The method is simple, safe and efficient, and has great application value and broad application prospects.

A method for inducing immature oocytes includes introducing four genes consisting of FIGLA, NOBOX, LHX8 and TBPL2, or transcripts or expressed proteins thereof, into at least one type of cell selected from the group consisting of pluripotent stem cells, epiblast-like cells and primordial germ cells. A method for producing mature oocytes includes introducing four genes consisting of FIGLA, NOBOX, LHX8 and TBPL2, or transcripts or expressed proteins thereof, into at least one type of cell selected from the group consisting of pluripotent stem cells, epiblast-like cells and primordial germ cells, and co-culturing the cell obtained after the introduction and ovarian somatic cells.